Clinical Trials Browser

Anus Neoplasms × Observation × 30 days × Clear all

NCT03233711 2026-05-13

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

Phase 3 Active not recruiting

Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms